placebo to formoterol
Sponsors
Novartis, Novartis Pharmaceuticals
Conditions
AsthmaCOPDChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)Lung Diseases, ObstructivePulmonary Disease, Chronic Obstructive
Phase 2
26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT00463567
Start: 2007-04-30End: 2008-08-31Updated: 2011-08-18
A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent Asthma
CompletedNCT00545272
Start: 2007-10-31End: 2008-04-30Updated: 2013-01-18
A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT00557466
Start: 2007-10-31End: 2008-05-31Updated: 2013-01-18
Phase 3
Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control
CompletedNCT00393458
Start: 2006-10-31End: 2008-07-31Updated: 2011-08-18
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT01574651
Start: 2012-05-31End: 2013-04-30Updated: 2014-05-22